Stocks Reaction on News: Stock Chemtura (NYSE:CHMT), McDermott International (NYSE:MDR), Antares Pharma (NASDAQ:ATRS), Morgan Stanley (NYSE:MS)
Chemtura Corp (NYSE:CHMT) reported that it has signed into a definitive contract to sell its agrochemicals business, Chemtura AgroSolutions, to Platform Specialty Products Corporation (PAH), a worldwide specialty chemicals company, for around $1 billion. In calendar 2013, on a pro-forma basis, including the elimination of any stranded costs associated with recent portfolio divestitures, Chemtura generated around $1.8B in net sales and $200M of Adjusted EBITDA.
Chemtura Corp (NYSE:CHMT) [Trend Analysis] reported the loss of -8.13% and closed at $23.16 with the total traded volume of 6.01 million shares. Its market capitalization is $2.22 billion. The company’s shares have fell -11.23% in the last one month and -12.59% in the previous three months, compared to an increase of 0.32% and 1.41% in the S&P 500 during the respective periods.
Get Free Inside Facts on (NYSE:CHMT)
McDermott International (NYSE:MDR) released that one of its subsidiaries has reached an option contract with PD Ports which gives it the select right to operate a spoolbase to serve projects in the North Sea. McDermott anticipates to have the facility available for projects in early 2015. Located in Hartlepool, in northeast United Kingdom, the spoolbase is expected to support McDermott’s re-entry into the North Sea Reel-Lay market.
McDermott International (NYSE:MDR) [Trend Analysis] gained 0.15%, closing the day at $6.87 in last regular trading. Corporation has the total of cash of $118.70 million as compares to total debt of $88.56 million for the most recent quarter with the current ratio of 0.96 for the most recent quarter.
Acts and Reacts in Analytic Report, Finds (NYSE:MDR)
Antares Pharma Inc (NASDAQ:ATRS) released that the Annals of the Rheumatic Diseases has published results from an open-label, head-to-head randomized, crossover study comparing the relative bioavailability, safety and tolerability of OTREXUP to oral methotrexate (MTX) in adult patients with rheumatoid arthritis.
In last trading session, shares of Antares Pharma Inc (NASDAQ:ATRS) [Trend Analysis] surged 0.99%, closing the day at $3.07, after wavering among $3.02 and $3.15 during the trading session. Its net profit margin in lasted declared quarter was -118.76% as compared to -99.46% in previous year in same year. Its beta value stands at 0.22 times.
What are Prospects of ATRS, Find the Free Technical Analysis
Morgan Stanley (NYSE:MS) released that its Q1 (Mar) earnings of $0.68 a share, $0.08 improved than the Capital IQ Consensus Estimate of $0.60. The firm revenues increased 9.6 percent year/year to $8.93B as compared the $8.55B consensus. Income from continuing operations applicable to Morgan Stanley was $1.5 billion, or $0.72 per diluted share, compared with income of $981 million, or $0.49 per diluted share, for the same period a year ago.
Morgan Stanley (NYSE:MS) [Trend Analysis] after opening at $30.72 hit its intraday high price of $31.29 moreover then finished at $30.76 by shares raised 2.91%. As took noticed on the firm sales growth (year/est), it is calculated 0.50% in Current Qtr. and for next quarter was forecasted 4.90%.
Moving Forces Behind (NYSE:MS) On Confident Run! Click Here
Read Full Disclaimer Here